Zobrazeno 1 - 10
of 618
pro vyhledávání: ''
Autor:
Edilmar Alvarado, Joan Genescà, Beatriz Peñas, Agustín Albillos, Carles Aracil, Rafael Bañares, José Luis Calleja, Maria A. Poca, Juan G. Abraldes, Rosa M Morillas, Càndid Villanueva, Ferran Torres, Jaume Bosch, Joan C Garcia-Pagan, Salvador Augustin
Publikováno v:
The Lancet. 393:1597-1608
Summary Background Clinical decompensation of cirrhosis is associated with poor prognosis. Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure gradient (HVPG) ≥10 mm Hg, is the strongest predictor of decompensati
Autor:
Gaetano Cantalupo, Giulia Galati, Jacopo Proietti, Anna Ludovica Ghobert, Tommaso Lo Barco, Francesca Lucca
Publikováno v:
The Lancet. 398:156
Autor:
Julián Panés, Adina Soaita, Wulf O. Böcher, Sudha Visvanathan, Kyung-Jo Kim, Bojan Lalovic, Paul Scholl, Ursula Seidler, Geert R. D'Haens, Steven J. Padula, Denis Franchimont, Arthur Kaser, Olivier Dewit, Edouard Louis, William J. Sandborn, Chandrasena Pamulapati, Stefan Schreiber, Brian G. Feagan, Markus F. Neurath, Ivona Herichova, Marc Ferrante, David B. Hall
Publikováno v:
Lancet, 389(10080), 1699-1709. Elsevier Limited
The Lancet, Vol. 389, no.10080, p. 1699-1709 (2017)
The Lancet, Vol. 389, no.10080, p. 1699-1709 (2017)
BACKGROUND: The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised mo
Autor:
Douglas G. Adler
Publikováno v:
The Lancet. 391:6-8
Autor:
Cristian Baicus
Publikováno v:
The Lancet. 393:1413-1414
Autor:
Richard W. Joseph, Christine Mateus, Amita Patnaik, Roxana S. Dronca, Omid Hamid, Adil Daud, F. Stephen Hodi, Scot Ebbinghaus, Wen-Jen Hwu, Jeroen Elassaiss-Schaap, Peter D. Boasberg, Richard F. Kefford, Antoni Ribas, Tara C. Gangadhar, S. Peter Kang, Bartosz Chmielowski, Anthony M. Joshua, Jedd D. Wolchok, Caroline Robert, Kevin Gergich, Hassane M. Zarour, Xiaoyun Nicole Li, Robert Iannone, Michael A. Postow, Jeffrey S. Weber
Publikováno v:
The Lancet. 384:1109-1117
Summary Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy and safety of pembrolizumab at doses of 2
Autor:
Enikő Mihály, Daniela Dobru, Dumitru Moldovan, Valentin Nădășan, Ramona Popa, Cătălin Dumitrache, Noémi Bara, Gabriella Gábos
Publikováno v:
The Lancet. 390:2119-2120
Autor:
Stephan B. Felix, Mario Schiffer, Sigrun Friesecke, Sylvia Stracke, Julia Mayerle, Friedlinde Ernst, Markus M. Lerch, Peter Abel, Jan T. Kielstein, Michael Fiene, Bernhard M W Schmidt, Karin Weissenborn, Kathleen Selleng, Alexander Dressel, Andreas Greinacher
Publikováno v:
The Lancet. 378:1166-1173
Summary Background In May 2011, an outbreak of Shiga toxin-producing enterohaemorrhagic E coli O104:H4 in northern Germany led to a high proportion of patients developing post-enteritis haemolytic uraemic syndrome and thrombotic microangiopathy that
Publikováno v:
The Lancet. 377:1600-1609
Primary biliary cirrhosis is a chronic liver disease characterised by intrahepatic bile-duct destruction, cholestasis, and, in some cases, cirrhosis. Evidence supporting the autoimmune nature of this disorder includes the appearance of highly specifi
Publikováno v:
The Lancet. 372:321-332
Symptomatic acute hepatitis C occurs in only about 15% of patients who are infected with hepatitis C virus (HCV). Acute hepatitis C is most often diagnosed in the setting of post-exposure surveillance, or seroconversion in high-risk individuals (eg,